☰

BioNTech SE

Connecting AI-driven discovery to live manufacturing data

Industry
Biopharmaceuticals (mRNA Therapeutics, Cell Therapy, Oncology)
Headquarters
Mainz, Rhineland-Palatinate, Germany
Public information as of
January 2026

A4BEE prepared this analysis from publicly available sources. It reflects our own reading of BioNTech SE's published strategy and is not endorsed by, or produced in cooperation with, BioNTech SE. Company website

Strategic priorities

BioNTech has set out to become a fully integrated multiproduct oncology company by 2030, and has said it will adjust resources across manufacturing, administrative functions and preclinical research over the next three years to support that shift. Total revenue moved from €3.8 billion in 2023 to €2.8 billion in 2024, producing a €0.7 billion net loss, while cash and cash equivalents stood at about €17.4 billion at year end. Theon-company ambition is to move past reliance on the Pfizer-BioNTech COVID-19 vaccine franchise and onto mRNA therapeutics, cell therapies and bispecific antibodies across multiple late-stage programmes.

The immediate operational priorities sit on three fronts. The mRNA platform acquired by the 2023 purchase of InstaDeep has to be wired to live manufacturing data, the modular BioNTainer network being built in Kigali, Rwanda and in Melbourne, Australia has to operate to harmonised GMP standards without on-site specialist staff, and the December 2024 acquisition of Biotheus has added a Chinese biologics manufacturing site and the bispecific antibody BNT327 to the technology estate. Each of these brings a new data shape to the integration problem.

Manufacturing capacity spans Mainz and Marburg in Germany, Idar-Oberstein, the Kigali BioNTainer facility and the Melbourne clinical site, with more than 6,100 employees globally. The work in a single batch involves on the order of 50,000 distinct operational steps and around 40 quality control tests, which makes every part of the data path from instrument to review queue material to cost-per-batch and to release time.

Public commitments line up behind that integration problem: a 42 percent reduction in absolute Scope 1 and 2 emissions by 2030 from a 2021 baseline reported in the 2024 Sustainability Report, and an mRNA capacity build-out designed around modular plug-and-produce cells rather than fixed facilities. Both depend on the same underlying capability that the rest of this page is about: process and quality data that can be read outside the equipment that produced it.

Challenges we see

  • Operations Manufacturing

    Coordinating the data path through a multi-batch mRNA process

    Each mRNA batch involves on the order of 50,000 distinct operational steps and around 40 quality control tests, with documentation generated in QC labs, in upstream and downstream processing, and in release review. The December 2024 acquisition of Biotheus added a new manufacturing site and a bispecific antibody programme.

    Where review and reconciliation is performed after the data has been captured, the population of records to reconcile is the whole batch. Capturing the same values as data on the way through leaves reconciliation as a check rather than as the route.

  • Digital Integration

    Linking discovery AI to live manufacturing data

    InstaDeep's generative protein and multiomics models were acquired in 2023 to make drug discovery digital-first, but the IT systems used for computational work remain disconnected from the OT layer that runs bioreactors and downstream processing.

    When the model sees a process only after the fact, the discovery loop turns on offline reports. Streaming the same values into the model while the run is live turns the loop into a continuous one and shortens the time between an observation and an update.

  • Digital Operations

    Unifying data from heterogeneous lab and process equipment

    Acquisitions including Biotheus and the growth of German sites have introduced a mix of lab and process equipment from vendors such as Hamilton, Roche and Beckman Coulter, much of which carries proprietary data formats.

    When each instrument produces values in its own dialect, the lab notebook or the spreadsheet becomes the only place where the data are aligned. Moving the alignment upstream into an OPC UA-based acquisition layer lets downstream systems consume a single format.

  • Operations Manufacturing

    Operating modular BioNTainer cells with limited on-site technical staff

    BioNTainer units in Kigali, Rwanda and in Melbourne, Australia are designed to run mRNA production to harmonised GMP standards in regions where on-site specialist technical support is thinner than at Mainz or Marburg. The COO has said digital solutions and automation are a prerequisite for the model.

    When a remote site depends on specialist travel for routine intervention, batch continuity depends on logistics rather than on the process. Remote monitoring and remote-assisted intervention let the specialist stay in the loop without being on site.

  • Compliance Regulatory

    Securing OT as the IT estate expands to feed AI analysis

    Connecting once-isolated OT systems to enterprise IT networks is necessary for AI-driven analysis and for the global visibility BioNTech describes, and it expands the attack surface for ransomware or industrial espionage against proprietary mRNA sequences.

    As the perimeter widens, network segmentation, identity controls and continuous monitoring become part of the GxP posture rather than a separate IT project, and the security baseline has to be designed in before production networks are bridged.

Opportunities, by urgency and business impact

Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.

Source: A4BEE analysis of public sources

  1. Capturing quality control results at the instrument

    Quality control results in QC labs are captured against paper or spreadsheet records, with biological KPIs tracked separately from live process trends. Each transfer between an instrument, a notebook and the release record is a separate transcription to perform and to verify.

    Connecting balances, plate readers and analysers through OPC UA (Open Platform Communications Unified Architecture) and writing their results into a LIMS or LES (Laboratory Execution System) with an audit trail attached shortens the release path and makes the evidence chain inspectable.

    • BioNTech Sustainability Report 2024
    • BioNTech SE Annual Report on Form 20-F for the year ended December 31, 2024

  2. Reading process signals during a 50,000-step batch

    Critical insights from bioreactors arrive days after a batch ends because the data path runs through offline Excel reports rather than the live process. The mRNA process is long and intricate enough that retroactive analysis does not catch a deviation in time to act on it.

    An industrial data platform streaming process values from bioreactors into a Golden Batch comparison lets the current run be evaluated against the historical best run while it is still running, with KPI dashboards shared between engineering and quality.

    • BioNTech Q4 2024 earnings call transcript
    • BioNTech, A sustainable solution to vaccine access in Africa (BioNTainer factsheet, 2022)

  3. Standardising modular cells with MTP

    BioNTainer modules from different vendors do not currently share a standard interface description, so swapping a drug substance or fill-finish module requires custom integration code rather than a plug-and-produce handover.

    Implementing the MTP (Module Type Package) standard to VDI/VDE/NAMUR 2658 lets module vendors describe their interfaces once and lets BioNTech integrate new skids against the same description, reducing integration effort and shortening setup time.

    • BioNTech, A sustainable solution to vaccine access in Africa (BioNTainer factsheet, 2022)
    • CEPI partnership announcement with BioNTech on the African mRNA vaccine ecosystem

  4. Predicting supply disruptions rather than reacting to them

    mRNA production depends on a small number of global suppliers for plasmid DNA, enzymes and specialised lipids. Lipid shortages delayed rollouts in 2021, and the company has no integrated predictive supply-chain platform to anticipate the next disruption.

    An industrial data platform with semantic models for raw materials, suppliers and inventory, plus predictive analytics on supplier lead times and geopolitical signals, shifts the supply chain from reactive to predictive.

    • PMC review article, Advancements and challenges in next-generation mRNA vaccine manufacturing systems

  5. Automating Scope 1 and 2 emissions reporting across the global estate

    Tracking Scope 1 and 2 emissions across Mainz, Marburg, Idar-Oberstein, Kigali, Melbourne and the new Chinese site is manual and error-prone, and the 42 percent reduction target for 2030 cannot be managed from year-end reports alone.

    IoT sensors on ultra-cold storage, HVAC and cleanroom systems feeding a cloud dashboard give real-time energy consumption by site and system, and feed automated SBTi-compliant reporting rather than manual aggregation.

    • BioNTech Sustainability Report 2024
    • BioNTech Sustainability Report 2023

What we'd propose

  • Digital Lab

    Vendor-agnostic QC data capture with OPC UA

    Connect QC lab instruments and bioreactor-side analysers through OPC UA so values arrive at the LIMS or LES as data with their own audit trail, eliminating paper notebooks and manual transcription from the release path.

    • OPC UA integration for heterogeneous instruments

      Connect Hamilton, Roche and Beckman Coulter in one path

      Build custom drivers and connectors to ingest data from the heterogeneous mix of QC and process instruments into a centralised acquisition layer using OPC UA as the vendor-neutral protocol, so data leaves each instrument in a documented form instead of staying inside proprietary software.

    • Digital workflow orchestration for QC

      Replace paper logbooks with electronic records

      Replace paper logbooks with electronic batch records that verify analyst training and instrument calibration status in real time, shifting from detective controls to preventive controls for ALCOA+ (the data integrity principles of Attributable, Legible, Contemporaneous, Original and Accurate).

    • GxP validation and audit trail

      Every value auditable from capture to release

      Implement validation packages and secure Room Gateways so every data operation is fully auditable under harmonised GMP standards, with high availability for the acquisition layer.

    • QC results reach the batch record as data carrying their own audit trail.
    • Manual transcription and the reconciliation steps that follow it leave the release path.
    • Inspection questions are answered from the record rather than from a reconstruction.

    We've done this before

    See how we do Digital Lab
  • Enterprise AI

    Industrial data platform for Golden Batch and live AI feedback

    A unified time-series and semantic data platform that streams process values from BioNTech's bioreactors into Golden Batch comparisons and into InstaDeep's discovery models, so manufacturing and discovery share one view of each batch while it is running.

    • Bio-KPI dashboard engine

      Twelve-plus bioprocess KPIs computed at the platform

      Automate the calculation of twelve or more critical bioprocess KPIs directly within the data platform, contextualising live sensor values into biological metrics that engineering, MSAT (Manufacturing Science and Technology) and quality can read together.

    • Golden Batch overlay

      Current run against historical best run

      Enable real-time overlay of the current run against historical best-run profiles so a deviation is flagged while the batch is still in progress, not after the report has been written.

    • IT to OT data bridge

      Discovery models see the running batch

      Build clean data pipelines from shop-floor sensors into InstaDeep's neural networks, so generative protein and multiomics models update against the values produced by the process rather than against offline summaries.

    • The same process values serve manufacturing, quality and discovery rather than three separate extracts.
    • Process deviations are visible to AI models at the same time as to engineers.
    • The discovery-to-manufacturing loop shortens from a batch cycle to the duration of a run.

    We've done this before

    See how we do Enterprise AI
  • Digital CDMO

    MTP-based plug-and-produce for BioNTainer modules

    An MTP library and integration framework that lets BioNTech integrate new BioNTainer modules against a standard interface description, making module swaps plug-and-produce rather than custom-coded integration projects.

    • MTP library to VDI/VDE/NAMUR 2658

      Standard interface descriptions for module vendors

      Deploy a comprehensive PLC library compliant with the MTP (Module Type Package) standard to VDI/VDE/NAMUR 2658, so each module vendor describes its interface once and BioNTech integrates new automation skids against that description.

    • Watchdog foam and process monitoring

      Computer vision for bioreactor-side incidents

      Deploy a Python and OpenCV-based computer vision system for non-invasive foam detection and autonomous antifoam dosing, which is critical for sites with limited on-site technical personnel such as the Kigali BioNTainer.

    • Remote operations baseline

      Designed for sites without specialist staff

      Establish a remote operations baseline covering secure connectivity, role-based access and shift handovers, so a remote BioNTainer cell can run to the same standard as a Mainz or Marburg site.

    • Module integration becomes a configuration task rather than an integration project.
    • New vendors can be onboarded against the same standard, widening the supply base.
    • Remote cells operate against the same process baseline as the central sites.

    We've done this before

    See how we do Digital CDMO
  • Enterprise AI

    Semantic supply chain platform for mRNA raw materials

    A semantic data platform that models plasmid DNA, enzymes and lipid suppliers, with predictive analytics on lead times and disruption signals, so the supply chain is managed forward rather than reacted to.

    • Semantic supply chain model

      One agreed description of every supplier

      Map physical supply chain parameters onto universal business classes using semantic ontologies, giving a unified view across plasmid DNA, enzyme and lipid suppliers and across the German, Rwandan and Australian sites.

    • Predictive inventory analytics

      Forecast disruption before it lands

      Deploy machine learning models that combine supplier performance data, geopolitical signals and demand patterns to flag disruption risk ahead of the order book.

    • Supplier visibility dashboard

      One view of GMP status and lead times

      Implement dashboards giving instant visibility into GMP supplier status, inventory levels and lead times across the global network, so a procurement team sees the same numbers as a planning team.

    • Disruption risk is named by the system rather than discovered when a shipment is late.
    • Supplier and inventory data live in one semantic model rather than across spreadsheets.
    • Procurement and planning see the same numbers on the same day.

    We've done this before

    See how we do Enterprise AI
  • Agents

    AI agents for regulatory and quality document work

    Narrow, reviewable agents that take the repetitive part of regulatory document work: drafting deviation and change-control summaries from source records, checking documents against templates before review, and finding every controlled document a standards change touches. A named person approves every output.

    • Drafting from source records

      First drafts from system data

      Generate the first draft of a deviation, change-control or periodic-review document directly from the underlying system records, so the author edits and judges rather than assembles.

    • Template and completeness checking

      Gaps found before review

      Check a submitted document against its template and the site's own checklist, returning missing or inconsistent sections before it enters the human review queue.

    • Change impact search across the document set

      Which documents a change touches

      When a standard, method or specification changes, retrieve every controlled document that references it and rank them by how directly they are affected, so the update scope is known on day one.

    • Review queues move faster because documents arrive complete.
    • The scope of a standards change is established by search rather than by recollection.
    • Every output is traceable to the source records it came from and signed off by a named reviewer.

    We've done this before

    See how we do Agents

Digital maturity: today and target

Scored out of 100 across six dimensions. The target is what BioNTech SE's own published ambition implies — not a perfect score.

Source: A4BEE analysis of public sources
Data integration 45 → 85
InstaDeep's AI is a corner of the platform rather than a peer to the manufacturing data layer. Heterogeneous lab and process equipment from Hamilton, Roche and Beckman Coulter still speaks proprietary formats in places.
Process automation 50 → 90
A 50,000-step batch with 40 quality control tests is the operating reality, and paper-based records remain part of the QC documentation path. The Lab-as-a-Platform work and the Biotheus site add new automation scope.
IT/OT convergence 35 → 80
Discovery algorithms and shop-floor sensors remain in separate estates. The BioNTainer model and the planned roll-out in Kigali and Melbourne make convergence a prerequisite rather than an aspiration.
Modular manufacturing 55 → 85
The BioNTainer concept is validated at the engineering level but module integration today is custom work. MTP standardisation would move modular manufacturing from a one-off capability to a repeatable programme.
Cybersecurity posture 40 → 75
Connecting once-isolated OT to enterprise IT to feed AI analysis widens the attack surface. The current posture has not yet been re-described against IEC 62443 (the international standard for industrial automation control system security) at the BioNTainer sites.
Sustainability intelligence 30 → 70
The 2030 target is a 42 percent reduction in absolute Scope 1 and 2 emissions from a 2021 baseline. Today the inputs come largely from year-end sustainability reporting rather than from continuous site-level measurement.

Check this yourself

Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.

Think we've read this right?

Talk to us

Related reading

This is an independent analysis prepared by A4BEE from publicly available information as of January 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with BioNTech SE, and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].